evans blue has been researched along with Diabetes Mellitus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bucolo, C; Dionysopoulou, S; Georgakis, S; Mastrodimou, N; Micale, V; Romano, GL; Spyridakos, D; Svensson, R; Thermos, K; Verginis, P; Walum, E; Wikstrom, P | 1 |
| Catanzaro, OL; Labal, ES; Lauria, LC; Obregon, P; Rodriguez, RR | 1 |
2 other study(ies) available for evans blue and Diabetes Mellitus
| Article | Year |
|---|---|
Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy.
Topics: Animals; Cytokines; Diabetes Mellitus; Diabetic Retinopathy; Evans Blue; NADPH Oxidase 4; NADPH Oxidases; Rats; Retina; Streptozocin; Vascular Endothelial Growth Factor A | 2023 |
Side effects of cyclosporine-A treatment in rats: gingival overgrowth and early hyperglycemia.
Topics: Animals; Blood Glucose; Capillary Permeability; Collagen; Coloring Agents; Cyclosporine; Diabetes Mellitus; Evans Blue; Gingiva; Gingival Overgrowth; Hyperglycemia; Immunosuppressive Agents; Male; Nitric Oxide; Random Allocation; Rats; Rats, Wistar; Time Factors | 2010 |